Follow-up Safety and Efficacy Evaluation on Subjects Who Completed the Initial Stage of PNEUMOSTEM Phase-II Clinical Trial
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Therapeutic Use
- Sponsors Medipost
- 18 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2020.
- 18 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2020.
- 16 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.